Trent Hoffman

Aug 9, 2023 | bioprocessonline.com | Tyler Menichiello |Trent Hoffman |Justin Nugent

By Tyler Menichiello, contributing editor If you’re still not excited about antibody drug conjugates (ADCs), “there’s an issue with you.” That’s the passionate, bullish sentiment (jokingly) held by Dr. Joe Daccache, project leader at DeciBio. Here, Daccache explains how innovations in linker technology are advancing the field of ADCs.

Aug 8, 2023 | pharmaceuticalonline.com | Trent Hoffman |Oliver Stauffer |James Fell |Barbara Schulz

By Jonathan B. (J.B.) Fitzgerald, Ph.D., and Trent L. Hoffman Snell & Wilmer attorneys discuss the recent SCOTUS decision to uphold the Federal Circuit's holding that Amgen’s patent claims for functionally claimed antibodies were invalid for failing to meet the enablement requirement. The attorneys share what this means for the industry going forward.

Jul 10, 2023 | drugdiscoveryonline.com | Trent Hoffman

Guest Column | July 10, 2023 By Jonathan B. (J.B.) Fitzgerald, Ph.D., and Trent L. Hoffman In Amgen v. Sanofi, on May 18, 2023, the Supreme Court upheld the Federal Circuit’s holding that Amgen’s patent claims for functionally claimed antibodies were invalid for failing to meet the enablement requirement.1 The Court’s ruling in Amgen has set a high bar for enabling functionally claimed biological compounds.